Articles published by Gilead Sciences, Inc.![]() ![]() ![]() ![]() ![]()
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
July 21, 2023
Via Business Wire
Tickers
GILD
![]()
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
July 20, 2023
Via Business Wire
Tickers
GILD
![]() ![]()
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
July 14, 2023
Via Business Wire
Tickers
GILD
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() Via Business Wire
Tickers
GILD
![]() ![]() Via Business Wire
Tickers
GILD
![]() ![]() ![]() Via Business Wire
Tickers
GILD
![]() Via Business Wire
Tickers
GILD
![]() ![]()
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
April 13, 2023
Via Business Wire
Tickers
GILD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|